{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:38:13Z","timestamp":1790386693744,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,10,2]],"date-time":"2013-10-02T00:00:00Z","timestamp":1380672000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s00280-013-2287-6","type":"journal-article","created":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T15:15:06Z","timestamp":1380640506000},"page":"1223-1234","source":"Crossref","is-referenced-by-count":79,"title":["Investigation into CYP3A4-mediated drug\u2013drug interactions on midostaurin in healthy volunteers"],"prefix":"10.1007","volume":"72","author":[{"given":"Catherine","family":"Dutreix","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Munarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Roesel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,10,2]]},"reference":[{"key":"2287_CR1","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","volume":"100","author":"DG Gilliland","year":"2002","unstructured":"Gilliland DG, Griffin JD (2002) The roles of FLT3 in hematopoiesis and leukemia. Blood 100:1532\u20131542","journal-title":"Blood"},{"key":"2287_CR2","first-page":"17","volume":"15","author":"D Fabbro","year":"2000","unstructured":"Fabbro D, Ruetz S, Bodis S, Pruschy M, Csermak K, Man A, Campochiaro P, Wood J, O\u2019Reilly T, Meyer T (2000) PKC412\u2013a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 15:17\u201328","journal-title":"Anticancer Drug Des"},{"key":"2287_CR3","unstructured":"Manley PW, Boulton C, Caravatti G, Gilliland DG, Griffin J, Kung A, Kelly L, Maira M, Mestan J, Meyer T, Ruetz S, Weisberg E, Fabbro D (2003) Preclinical profile of PKC412 (Midostaurin) as an FLT3 inhibitor for the therapy of AML. In: 94th AACR annual meeting, poster 1004"},{"key":"2287_CR4","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1182\/blood-2006-04-015743","volume":"108","author":"M Levis","year":"2006","unstructured":"Levis M, Brown P, Smith BD, Stine A, Pham R, Stone R, Deangelo D, Galinsky I, Giles F, Estey E, Kantarjian H, Cohen P, Wang Y, Roesel J, Karp JE, Small D (2006) Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood 108:3477\u20133483","journal-title":"Blood"},{"key":"2287_CR5","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2165\/0003088-200847120-00005","volume":"47","author":"OQ Yin","year":"2008","unstructured":"Yin OQ, Wang Y, Schran H (2008) A mechanism-based population pharmacokinetic model for characterizing time-dependent pharmacokinetics of midostaurin and its metabolites in human subjects. Clin Pharmacokinet 47:807\u2013816","journal-title":"Clin Pharmacokinet"},{"key":"2287_CR6","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1177\/0091270008318006","volume":"48","author":"Y Wang","year":"2008","unstructured":"Wang Y, Yin OQ, Graf P, Kisicki JC, Schran H (2008) Dose- and time-dependent pharmacokinetics of midostaurin in patients with diabetes mellitus. J Clin Pharmacol 48:763\u2013775","journal-title":"J Clin Pharmacol"},{"key":"2287_CR7","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/00062752-200207000-00003","volume":"9","author":"DG Gilliland","year":"2002","unstructured":"Gilliland DG, Griffin JD (2002) Role of FLT3 in leukemia. Curr Opin Hematol 9:274\u2013281","journal-title":"Curr Opin Hematol"},{"key":"2287_CR8","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2009-03-209999","volume":"114","author":"S Kayser","year":"2009","unstructured":"Kayser S, Schlenk RF, Londono MC, Breitenbuecher F, Wittke K, Du J, Groner S, Spath D, Krauter J, Ganser A, Dohner H, Fischer T, Dohner K, German-Austrian AML Study Group (AMLSG) (2009) Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood 114:2386\u20132392","journal-title":"Blood"},{"key":"2287_CR9","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","volume":"108","author":"AC Garcia-Montero","year":"2006","unstructured":"Garcia-Montero AC, Jara-Acevedo M, Teodosio C, Sanchez ML, Nunez R, Prados A, Aldanondo I, Sanchez L, Dominguez M, Botana LM, Sanchez-Jimenez F, Sotlar K, Almeida J, Escribano L, Orfao A (2006) KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish network on mastocytosis (REMA) in a series of 113 patients. Blood 108:2366\u20132372","journal-title":"Blood"},{"key":"2287_CR10","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1038\/leu.2012.115","volume":"26","author":"RM Stone","year":"2012","unstructured":"Stone RM, Fischer T, Paquette R, Schiller G, Schiffer CA, Ehninger G, Cortes J, Kantarjian HM, Deangelo DJ, Huntsman-Labed A, Dutreix C, Del Corral A, Giles F (2012) Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia 26:2061\u20132068","journal-title":"Leukemia"},{"key":"2287_CR11","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1200\/JCO.2010.28.9678","volume":"28","author":"T Fischer","year":"2010","unstructured":"Fischer T, Stone RM, DeAngelo DJ, Galinsky I, Estey E, Lanza C, Fox E, Ehninger G, Feldman EJ, Schiller GJ (2010) Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol 28:4339\u20134345","journal-title":"J Clin Oncol"},{"key":"2287_CR12","doi-asserted-by":"crossref","unstructured":"Stone RM, Dohner H, Ehninger G, Villeneuve M, Teasdale T, Virkus JD, Bressler LR, Seiler MM, Marcucci G, Larson RA, and on behalf of all study investigators (2011) CALGB 10603 (RATIFY): a randomized phase III study of induction (daunorubicin\/cytarabine) and consolidation (high-dose cytarabine) chemotherapy combined with midostaurin or placebo in treatment-naive patients with FLT3 mutated AML. J Clin Oncol 29:31s( abstract TPS199)","DOI":"10.1200\/jco.2011.29.15_suppl.tps199"},{"key":"2287_CR13","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","volume":"113","author":"KH Lim","year":"2009","unstructured":"Lim KH, Tefferi A, Lasho TL, Finke C, Patnaik M, Butterfield JH, McClure RF, Li CY, Pardanani A (2009) Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 113:5727\u20135736","journal-title":"Blood"},{"key":"2287_CR14","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0145-2126(02)00168-6","volume":"27","author":"P Valent","year":"2003","unstructured":"Valent P, Akin C, Sperr WR, Escribano L, Arock M, Horny HP, Bennett JM, Metcalfe DD (2003) Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res 27:635\u2013641","journal-title":"Leuk Res"},{"key":"2287_CR15","doi-asserted-by":"crossref","unstructured":"Gotlib J, DeAngelo DJ, George TI, Corless CL, Linder A, Langford C, Dutreix C, Gross S, Nikolova Z, Graubert T (2010) KIT inhibitor midostaurin exhibits a high rate of clinically meaningful and durable responses in advanced systemic mastocytosis: report of a fully accrued phase II trial. Blood 116 (abstract 316)","DOI":"10.1182\/blood.V116.21.316.316"},{"key":"2287_CR16","doi-asserted-by":"crossref","unstructured":"Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O, Awan F, Hexner E, Mauro M, Morariu R, Squier M, Villeneuve M, Emery-Salbert F, Hartmann K, Horny HP, Valent P, Reiter A (2012) KIT inhibitor midostaurin in patients with advanced systemic mastocytosis: results of a planned interim analysis of the global CPKC412D2201 trial. Blood 120:21(abstract 799)","DOI":"10.1182\/blood.V120.21.799.799"},{"key":"2287_CR17","doi-asserted-by":"crossref","unstructured":"Yin O, Wang Y, Lanza C, Schimansky T, Balez S, Schran HF, Stone RM (2008) Pharmacokinetics (PK) and pharmacodynamics (PD) of midostaurin (PKC412) in patients with acute myeloid leukemia (AML). J Clin Oncol 26:15s(abstract 706)","DOI":"10.1200\/jco.2008.26.15_suppl.7064"},{"key":"2287_CR18","unstructured":"Absorption, metabolism, and excretion of midostaurin in healthy volunteers. Manuscript in preparation"},{"key":"2287_CR19","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.2001.19.5.1485","volume":"19","author":"DJ Propper","year":"2001","unstructured":"Propper DJ, McDonald AC, Man A, Thavasu P, Balkwill F, Braybrooke JP, Caponigro F, Graf P, Dutreix C, Blackie R, Kaye SB, Ganesan TS, Talbot DC, Harris AL, Twelves C (2001) Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol 19:1485\u20131492","journal-title":"J Clin Oncol"},{"key":"2287_CR20","unstructured":"US Food and Drug Administration (FDA) (2012) Guidance for Industry. In vivo drug metabolism\/drug interaction studies\u2014study design, data analysis, implications for dosing, and labeling recommendations"},{"key":"2287_CR21","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/clpt.2008.132","volume":"84","author":"KP Kanebratt","year":"2008","unstructured":"Kanebratt KP, Diczfalusy U, Backstrom T, Sparve E, Bredberg E, Bottiger Y, Andersson TB, Bertilsson L (2008) Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol. Clin Pharmacol Ther 84:589\u2013594","journal-title":"Clin Pharmacol Ther"},{"key":"2287_CR22","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/FPC.0b013e3282f50ee9","volume":"18","author":"U Diczfalusy","year":"2008","unstructured":"Diczfalusy U, Miura J, Roh HK, Mirghani RA, Sayi J, Larsson H, Bodin KG, Allqvist A, Jande M, Kim JW, Aklillu E, Gustafsson LL, Bertilsson L (2008) 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenet Genomics 18:201\u2013208","journal-title":"Pharmacogenet Genomics"},{"key":"2287_CR23","unstructured":"Dutreix C, Schmitt A, Munarini F, Lorenzo S, Schran H, Wang Y (2011) Effects of ketoconazole and rifampicin on the pharmacokinetics of midostaurin in healthy subjects. Basic Clin Pharmacol Toxicol 109:s1(abstract P5)"},{"key":"2287_CR24","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1124\/dmd.105.006874","volume":"34","author":"A Galetin","year":"2006","unstructured":"Galetin A, Burt H, Gibbons L, Houston JB (2006) Prediction of time-dependent CYP3A4 drug\u2013drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab Dispos 34:166\u2013175","journal-title":"Drug Metab Dispos"},{"key":"2287_CR25","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/dmd.31.7.815","volume":"31","author":"TD Bjornsson","year":"2003","unstructured":"Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA (2003) The conduct of in vitro and in vivo drug\u2013drug interaction studies: a pharmaceutical research and manufactures research and manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815\u2013832","journal-title":"Drug Metab Dispos"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-013-2287-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2287-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2287-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T04:07:14Z","timestamp":1596600434000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-013-2287-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,2]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["2287"],"URL":"https:\/\/doi.org\/10.1007\/s00280-013-2287-6","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,2]]}}}